Huailong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huailong Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bo Li
Department of Cardiovascular Medicine, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524000, China
1 shared publication - Can Chen
Department of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
1 shared publication - Congxin Huang
Department of Cardiology Renmin Hospital of Wuhan University Wuhan China
1 shared publication - Jianfeng Zhong
Department of Cardiovascular Medicine, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524000, China
1 shared publication - Wei Lei
Precision Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
1 shared publication - Wenjiang Chen
Department of Cardiovascular Medicine, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524000, China
1 shared publication
Latest Publications
- Open Access
- 17 February 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 18
Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease
Coronary artery disease (CAD) is one of the most common diseases leading to mortality and morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1) levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no study has specifically addressed levels in patients with different degrees of CAD severity.
- 17 February 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 18
Open AccessSerum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease
Coronary artery disease (CAD) is one of the most common diseases leading to mortality and morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1) levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no study has specifically addressed levels in patients with different degrees of CAD severity.